China – based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the completion of enrollment for its Phase III study of RAY1216, a drug candidate for the treatment of mild SARS – CoV – 2 infection. The randomized, double – blind, placebo – controlled study has enrolled 1,360 subjects who will receive RAY1216 orally for five consecutive days. The primary endpoint of the study is the duration of clinical symptom recovery.
Mechanism of Action and Clinical Profile
RAY1216 is designed to inhibit 3CL protease, a key enzyme in the replication of COVID – 19. The drug has demonstrated a clear mechanism of action and a good safety, tolerability, and pharmacokinetic profile in a completed Phase I clinical study. A dose – exploratory study showed that RAY1216, when combined with ritonavir, could rapidly reduce the RNA load of COVID – 19 and shorten the time required for viral nucleic acid to convert to negative. This combination therapy has shown significant potential in treating mild COVID – 19 infections.
Future Prospects and Impact
The completion of enrollment in the Phase III study marks a significant milestone in the development of RAY1216. If successful, the drug could provide a new and effective treatment option for patients with mild COVID – 19 infections, potentially reducing the duration of illness and improving patient outcomes. Guangdong Zhongsheng’s commitment to advancing RAY1216 underscores its dedication to addressing the ongoing challenges posed by the COVID – 19 pandemic.-Fineline Info & Tech
